Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerd Mikus

Showing results (141-150 of 194) with videos related to

Pageof 20
Sort By:
British Journal of Clinical Pharmacology|July 10, 2003
Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interactionJens Rengelshausen, Christoph Göggelmann, Jürgen Burhenne, et al.
Journal of Clinical Pharmacology|November 27, 2008
CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazoleJohanna Weiss, Magdalena Maria Ten Hoevel, Jürgen Burhenne, et al.
Pharmacology|October 30, 2008
Meeting the challenges of opioid-induced constipation in chronic pain management - a novel approachKaren Reimer, Michael Hopp, Michael Zenz, et al.
Journal of Clinical Pharmacology|December 29, 2006
Significant pharmacokinetic and pharmacodynamic interaction of warfarin with the NO-independent sGC activator HMR1766Heike Oberwittler, Andreas Hirschfeld-Warneken, Roland Wesch, et al.
International Journal of Medical Informatics|February 4, 2014
What, if all alerts were specific - estimating the potential impact on drug interaction alert burdenHanna M Seidling, Ulrike Klein, Matthias Schaier, et al.
Cardiovascular Drugs and Therapy|March 4, 2023
Effect of Clarithromycin, a Strong CYP3A and P-glycoprotein Inhibitor, on the Pharmacokinetics of Edoxaban in Healthy Volunteers and the Evaluation of the Drug Interaction with Other Oral Factor Xa Inhibitors by a Microdose Cocktail ApproachAlexander Lenard, Simon A Hermann, Felicitas Stoll, et al.
Clinical Pharmacology and Therapeutics|August 8, 2006
Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavirGerd Mikus, Verena Schöwel, Magdalena Drzewinska, et al.
Journal of the American Society of Nephrology : JASN|March 7, 2000
Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover studyChristiane Pauli-Magnus, Gerd Mikus, Dominik M Alscher, et al.
Clinical Pharmacokinetics|October 4, 2022
Quantification of the Time Course of CYP3A Inhibition, Activation, and Induction Using a Population Pharmacokinetic Model of Microdosed Midazolam Continuous InfusionYomna M Nassar, Nicolas Hohmann, Robin Michelet, et al.
Basic & Clinical Pharmacology & Toxicology|October 8, 2014
The effect of induction of CYP3A4 by St John's wort on ambrisentan plasma pharmacokinetics in volunteers of known CYP2C19 genotypeChristoph Markert, Ida Maria Kastner, Regina Hellwig, et al.
Pageof 20

Showing results (141-150 of 194) with videos related to

Sort By:
Pageof 20
British Journal of Clinical Pharmacology|July 10, 2003
Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interactionJens Rengelshausen, Christoph Göggelmann, Jürgen Burhenne, et al.
Journal of Clinical Pharmacology|November 27, 2008
CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazoleJohanna Weiss, Magdalena Maria Ten Hoevel, Jürgen Burhenne, et al.
Pharmacology|October 30, 2008
Meeting the challenges of opioid-induced constipation in chronic pain management - a novel approachKaren Reimer, Michael Hopp, Michael Zenz, et al.
Journal of Clinical Pharmacology|December 29, 2006
Significant pharmacokinetic and pharmacodynamic interaction of warfarin with the NO-independent sGC activator HMR1766Heike Oberwittler, Andreas Hirschfeld-Warneken, Roland Wesch, et al.
International Journal of Medical Informatics|February 4, 2014
What, if all alerts were specific - estimating the potential impact on drug interaction alert burdenHanna M Seidling, Ulrike Klein, Matthias Schaier, et al.
Cardiovascular Drugs and Therapy|March 4, 2023
Effect of Clarithromycin, a Strong CYP3A and P-glycoprotein Inhibitor, on the Pharmacokinetics of Edoxaban in Healthy Volunteers and the Evaluation of the Drug Interaction with Other Oral Factor Xa Inhibitors by a Microdose Cocktail ApproachAlexander Lenard, Simon A Hermann, Felicitas Stoll, et al.
Clinical Pharmacology and Therapeutics|August 8, 2006
Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavirGerd Mikus, Verena Schöwel, Magdalena Drzewinska, et al.
Journal of the American Society of Nephrology : JASN|March 7, 2000
Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover studyChristiane Pauli-Magnus, Gerd Mikus, Dominik M Alscher, et al.
Clinical Pharmacokinetics|October 4, 2022
Quantification of the Time Course of CYP3A Inhibition, Activation, and Induction Using a Population Pharmacokinetic Model of Microdosed Midazolam Continuous InfusionYomna M Nassar, Nicolas Hohmann, Robin Michelet, et al.
Basic & Clinical Pharmacology & Toxicology|October 8, 2014
The effect of induction of CYP3A4 by St John's wort on ambrisentan plasma pharmacokinetics in volunteers of known CYP2C19 genotypeChristoph Markert, Ida Maria Kastner, Regina Hellwig, et al.
Pageof 20